Rucaparib (AG-014699) phosphate

Catalog No.S1098 Synonyms: PF-01367338

For research use only.

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Rucaparib (AG-014699) phosphate Chemical Structure

CAS No. 459868-92-9

Selleck's Rucaparib (AG-014699) phosphate has been cited by 107 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Other PARP Products

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 MX\GeY5kfGmxbjDBd5NigQ>? MYCwMlEwOS93MECvNVAxOCCwTR?= M4q4Z4lvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6P NGTncmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
BT474 M3XvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TiOVUxOCCwTR?= NVLOWIJnOTEkgKOxOeKh\A>? M2LKdJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> M17uVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
SKBR3 M{LYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjyOYFLPTByIH7N M1v6TlEx6oDVMUZCpIQ> NY\QeJZnemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
AU565 NU\FXXdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPFO3M2ODBibl2= NWntNpdtOTEkgKOxOeKh\A>? MVXy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 NX:0cVJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
EFM192A Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfJOVAxKG6P M1G2U|Ex6oDVMUZCpIQ> MlfMdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> NV;s[HNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
MDA-MB-231 NUjSXG9yTnWwY4Tpc44hSXO|YYm= M2noXlExNzJyL{SwJO69VQ>? NUTMZWlJOjRiaB?= Moe5bY5kemWjc3XzJJAuSUuWIHzleoVteyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGWxdYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231 NUHnN5BjS2WubDDWbYFjcWyrdImgRZN{[Xl? NGTTOFUxNjFvNECg{txO NWDRdI9rOjRiaB?= MWPJR|Ux6oDLPfMAjVE4Njd5wrFOwG0> MmqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 M{izT2Fxd3C2b4Ppd{BCe3OjeR?= NX7FUpRMOTBxMkCvOFAh|ryP M2XPdlI1KGh? MlvRbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NGr1cYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231 M{j1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxNE8zOC92MDFOwG0> M{\GRVI1KGh? MYnicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn NF3uWHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
H460 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HM[lQxOCCwTR?= MXiyOOKhcA>? NU[0bXR4cW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> M12wWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxOlEyLz5{NESxNVYyOTxxYU6=
A549  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKzPWQ1ODBibl2= MkX0NlTDqGh? Ml\RbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUG2NVEoRjJ2NEGxOlEyRC:jPh?=
DT40 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K1SGlEPTB;MkGgcm0> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR|NU[4NVM9N2F-
DU145 M4j5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF6IH7N M3SwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W2PFE{Lz5{NEO1OlgyOzxxYU6=
COLO704 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwNUKgxtEhOC54NzFOwG0> M{XJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVMANAb MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwNUigxtEhOC5|ODFOwG0> NH;VTVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV177 M17Zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjicoJKSzVyPUKuO|ghyrFiMD63NUDPxE1? M4LQS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW28 NVH2R5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HzWGlEPTB;Mz62NUDDuSByLkK4JO69VQ>? M3nP[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVSAHO M1fWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG1TWM2OD1|Lk[0JOKyKDBwM{Og{txO MmPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVKATE NX2zcFNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnGNGk6UUN3ME2zMlY1KMLzIEGuO|kh|ryP MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCAR3 NHvkc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwN{SgxtEhOC52MDFOwG0> NUjFVYFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
PEO14 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwOESgxtEhOC55NjFOwG0> NHjUdGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
A2780 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhXm9KSzVyPUOuPVQhyrFiMD6yOUDPxE1? MmPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVTOKO NWfMRYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD12LkG0JOKyKDFwNUOg{txO MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KURAMOCHIb NWO3RZJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;XTWM2OD12LkO0JOKyKDBwMkmg{txO NHnqNYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
TOV21G NH;0W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrXWVJxUUN3ME21MlA4KMLzIEGuN|Ah|ryP NE\SZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVISE NITNV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ThWGlEPTB;NT62PEDDuSByLkKzJO69VQ>? NEfKNZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KK NWrWT3o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33tSGlEPTB;Nj6xOUDDuSBzLkSyJO69VQ>? NXL3XmpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
RMUGS NX7FPXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTiZnZNUUN3ME23MlA{KMLzIEGuPFMh|ryP M3P0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
PEO6 NXzQ[oY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmemtoUUN3ME23MlA3KMLzIECuO|Qh|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCA429 NEXJeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu0SmpKSzVyPUiuNlkhyrFiMT62OEDPxE1? M3;3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV167 NHTOeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRThwM{OgxtEhOS5zODFOwG0> MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
RMG1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrPTWM2OD17LkOyJOKyKDJwM{[g{txO MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCAR5 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTlwNUCgxtEhOi53OTFOwG0> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO21 NUjrRpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTlwOUKgxtEhOS56NzFOwG0> Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
ES2 NWO5[3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFyLkGyJOKyKDFwMkOg{txO NUPIbod5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
Tyk-nu MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DIN2lEPTB;MUCuNlAhyrFiMT6xNkDPxE1? MofNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
CAOV3 NGHmUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFyLkO3JOKyKDBwOEeg{txO MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OV207 NYS2SW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\WTWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? M164bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
HEY MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjsTWM2OD1zMz6wNUDDuSByLke1JO69VQ>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
DOV13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzCPGluUUN3ME6xOUDPxE1? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO27 M4TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRjF3IN88US=> NFrmWno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
HEY C2 NYTGeotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJVIk2UUN3ME6xOUDPxE1? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KOC-7cc M2nuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ubJlKSzVyPkG1JO69VQ>? NILrXo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
MCASb NH74RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnZbo1KSzVyPkG1JO69VQ>? NYTsWnZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OAW42 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1V4pKSzVyPkG1JO69VQ>? NHjRbXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV2008 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD5zNTFOwG0> Mlm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV90 M17T[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;mdWg2UUN3ME6xOUDPxE1? NH;4NoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA420b MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXTWM2OD5zNTFOwG0> M2PyW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCA432 NInGTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHRXXhKSzVyPkG1JO69VQ>? M{\xeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
PEA2 M{H1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFNFhKUUN3ME6xOUDPxE1? MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
SKOV3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRjF3IN88US=> Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
TOV112D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLpdFZUOC1|IN88US=> MU\JR|UxRjF3IN88US=> M4D5O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
C4-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzMfmtkOC1|IN88US=> MUmxOEBl MkHFSG1UVw>? NFS2Z21l\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
PC3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGNE0{KM7:TR?= NIq3bFQyPCCm MWrEUXNQ Mmrz[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
DU145 M2L0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;uSlAuOyEQvF2= M4rFSFE1KGR? M17oZmROW09? MYnk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 MorGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
VCaP  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTrXHUxOC1|IN88US=> M3zReVE1KGR? MmK2SG1UVw>? MWPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NVzEOmxFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
LNCaP  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\IXpozOC1|IN88US=> MoDpNVQh\A>? M4PUbWROW09? MXvk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NGKwU|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
MDA-MB-468 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlvnTWM2OD17Lkeg{txO NF;KN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
MDA-MB-231 M17Ne2NmdGxiVnnhZoltcXS7IFHzd4F6 NUflemdZUUN3ME2xN{DPxE1? NX;0cVZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O|gyPjFpPkKyOlc5OTZzPD;hQi=>
Cal-51 NHm0R2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGHvOlNKSzVyPUiuOkDPxE1? NHTVU2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
LoVo MWPGeY5kfGmxbjDhd5NigQ>? NV7GcGpmOzBibXnudy=> MkDkTY5pcWKrdHnvckBw\iCSQWLQJIlvKGi3bXHuJGxwXm9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7KFHEVEkuemmkb4PlJJBwdHmvZYLpfoF1cW:wIH\vdkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwMEC0Olkh|ryPLh?= Mn\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MX1 M3mzOWN6fG:2b4jpZ4l1gSCjc4PhfS=> MmfwR5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUGt[IVncWOrZX70JIh2dWGwIF3YNUBk\WyuczygSWM2OCB;IECuNFA2OyEQvF2u NV;QfoFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
Rosetta2 (DE3) M3e5ZWZ2dmO2aX;uJIF{e2G7 NX;aRXcyUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIE\4bIl{NXSjZ3fl[EBCWlSGNjCoPFc{KHSxIEGxOlEqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIGLvd4V1fGF{IDjESVMqKGOnbHzzJJV{cW6pIF7BSEsh[XNic4Xid5Rz[XSnIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4> M4\pSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
Rosetta2 (DE3) MYPGeY5kfGmxbjDhd5NigQ>? M3rJOWlvcGmkaYTpc44hd2ZiaIXtZY4hPniqaYOteIFo\2WmIFHSWGQ2KChzMEOwJJRwKDF|MUepJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKFKxc3X0eIEzKCiGRUOpJINmdGy|IIXzbY5oKE6DRDugZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFI2KM7:TT6= MlHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3O|AoRjJ2OUCwO|cxRC:jPh?=
LoVo NX3QO3F5S3m2b4TvfIlkcXS7IHHzd4F6 NV6xW5ZJOC52IIXN NIS1cZM2KGSjeYO= NHzIfHRRd3SnboTpZZRqd25ib3[geIVud3qxbH;tbYRmNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHnuJIh2dWGwIFzvWo8h[2WubIOgZZN{\XO|ZXSgZZMhfGWvb4rvcI9ucWSnIFfJOVAh[XRiMD60JJVOKGGodHXyJFUh\GG7czDifUBE\WyudHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5zNESg{txONg>? M3XXOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
Capan1 NIj0WFlEgXSxdH;4bYNqfHliYYPzZZk> M1r3UGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GyMYRm\mmlaXXueEBpfW2jbjDDZZBidjFiY3XscJMtKEWFNUCgQUAxNjZyOTFOwG0v MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MDA-MB-436 MnLJRY51cWOjbnPldkBie3OjeR?= MlrHPVYhcHK| MV7BcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmLDRVEu\GWoaXPp[Y51KE2GQT3NRk01OzZiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFMh|ryPLh?= M4[0b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{SyPFY5Lz5{NkO0Nlg3QDxxYU6=
OVCAR3 NGm3NItCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnPONlQhcHK| M3vsOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI{KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCzMlMyKM7:TT6= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3NkGwOkc,Ojl2NU[xNFY9N2F-
MRC5 Mlr6R5l1d3SxeHnjbZR6KGG|c3H5 MkGwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{whTUN3MDC9JFgvPTNizszNMi=> Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MCF7 M1ewVWFvfGmlYX7j[ZIh[XO|YYm= M3yzV|k3KGi{cx?= Ml\5RY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEG5MlQ4KM7:TT6= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN2Mki2PEc,OjZ|NEK4Olg9N2F-
A673 MlTVdWhVWyCjc4PhfS=> NUG0WW1IeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NIjSU3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 Ml;1dWhVWyCjc4PhfS=> MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> M4ezd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 M1;6W5FJXFNiYYPzZZk> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MnHtdWhVWyCjc4PhfS=> NWXYPWE{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NFy4SWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 MYDxTHRUKGG|c3H5 M2[2bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Assay
Methods Test Index PMID
Western blot BRCA1 ; PAR 24085845 27960087
Growth inhibition assay Cell viability 31119062
Immunofluorescence 53BP1 ; γH2AX ; PAR ; α-tubulin 23565244 27515310 30589644
In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol (from reference)

Kinase Assay:[1]
  • Ki Determination:

    Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.

Cell Research:[4]
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
  • (Only for Reference)
Animal Research:[4]
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 84 mg/mL
(199.35 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AG-014699|AG-014699 ic50|AG-014699 price|AG-014699 cost|AG-014699 solubility dmso|AG-014699 purchase|AG-014699 manufacturer|AG-014699 research buy|AG-014699 order|AG-014699 mouse|AG-014699 chemical structure|AG-014699 mw|AG-014699 molecular weight|AG-014699 datasheet|AG-014699 supplier|AG-014699 in vitro|AG-014699 cell line|AG-014699 concentration|AG-014699 nmr|AG-014699 in vivo|AG-014699 clinical trial|AG-014699 inhibitor|AG-014699 DNA Damage inhibitor